Myomo (MYO) Total Non-Current Liabilities (2016 - 2025)

Myomo (MYO) posted Total Non-Current Liabilities of $25.6 million for Q4 2025, up 509.38% on a QoQ basis from $4.2 million in Q3 2021.

Myomo (MYO) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends

Myomo's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $25.6 million for Q4 2025.

Quarterly Total Non-Current Liabilities changed N/A year-over-year to $25.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.6 million (changed N/A YoY) and the FY2025 annual result came in at $25.6 million, changed N/A from the prior year.
Total Non-Current Liabilities was $25.6 million for Q4 2025 at Myomo, up from $4.2 million in the prior quarter.
Across five years, Total Non-Current Liabilities topped out at $25.6 million in Q4 2025 and bottomed at $3.8 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	20.94 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	41.44 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	41.88 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	2.64 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	3.53 Bn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	9.85 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	24.21 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	3.57 Bn
10	Myomo	39.24 Mn	20.27 Mn	-	25.58 Mn

Download Data